Nuria Garcia Diaz

Bilde av Nuria Garcia Diaz
English version of this page
Besøksadresse Ullernchausseen 70 OUS Radiumhospitalet 0372 Oslo
Postadresse Postboks 4950 Nydalen OUS, Rikshospitalet 0424 Oslo
Emneord: Cell signalling, Cancer research, Immunology, cancer immunotherapy

Utvalgte publikasjoner


García-Díaz, N; Piris, MA; Ortiz-Romero, PL and Vaqué, JP. Mycosis fungoides and Sézary syndrome: diagnosis, molecular drivers and therapy. Cancers 2021.

Alonso-Alonso, R; Mondéjar, R; Martínez, N; García-Diaz, N; […]; Scholz, C; Vaqué, JP; Gualberto, A; Piris, MÁ. Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma. Scientific Reports 2020.

Pérez, C; Mondéjar, R; García-Díaz, N; Cereceda, L; […]; Martínez, N; Vaqué, JP; Ortiz-Romero, PL; Piris, MA. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways. British Journal of Dermatology 2019.

Ruso-Julve, F; Pombero, A; Pilar-Cuéllar, F; García-Díaz, N; […]; Gonzalez-Maeso, J; Martínez, S; Vaqué, JP; Crespo-Facorro, B. Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK molecular effects of antipsychotics. Translational psychiatry 2019.

Llerena, S*; García-Díaz, N*; Curiel-Olmo, S; Agraz-Doblas, A; […]; Varela, I; Piris, MÁ; Crespo, J; Vaqué, JP.  Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget 2018. *Contributed equally.

Pérez, C; González-Rincón, J; Onaindia, A; Almaráz, C; García-Díaz, N; […]; Ortiz-Romero, P; Sánchez-Beato, M; Piris, MÁ; Vaqué, JP. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. Haematologica 2015.

Curiel-Olmo, S; García-Castaño, A; Vidal, R; Pisonero, H; Varela, I; León-Castillo, A; Trillo, E; González-Vela, C; García-Díaz, N; […]; Ortiz-Romero, P; Valdizán, E; Piris, MA; Vaqué, JP. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. Oncotarget 2015.

Publisert 6. okt. 2021 15:39 - Sist endret 7. okt. 2021 09:56